Syril Dorairaj, MD
Ophthalmology · Jacksonville, FLNPI 1295992550
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $279,404 of the $432,059 with a category attached, or 64.7%. 11 manufacturers reported payments, led by Iridex Corporation at 55.2% of the total. Reporting peaked in 2022 at $197,627 and has fallen 89.7% since, to $20,337 in 2025. Among ophthalmology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 351 payments — averaging $1230.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Iridex Corporation$238K
- NEW World Medical,inc.$169K
- Sight Sciences, Inc.$12K
- Glaukos Corporation$6K
- AbbVie$5K
- Johnson & Johnson Surgical Vision, Inc.$557
- plus $915 from 5 others
Across 20 payments — averaging $9118.71 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- NEW World Medical,inc.$137K
- AbbVie$44K
- Alcon Research LLC$1K
What the payments were for
- Consulting fees$22,1225%
- Speaking & faculty fees$279,40465%
- Travel & lodging$108,57225%
- Food & beverage$21,9625%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Iridex Corporation | 26 | $238,397 |
| NEW World Medical,inc. | 190 | $169,262 |
| Sight Sciences, Inc. | 44 | $12,410 |
| Glaukos Corporation | 30 | $5,790 |
| AbbVie(2 entities) | 33 | $4,730 |
| Johnson & Johnson Surgical Vision, Inc. | 13 | $557 |
| Alcon | 8 | $407 |
| Ivantis, Inc | 3 | $237 |
| Rxsight Inc | 1 | $131 |
| Aerie Pharmaceuticals, Inc. | 2 | $75 |
| Carl Zeiss Meditec, Inc. | 1 | $65 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ahmed Glaucoma Valve$149,634
- Kahook Dual Blade$148,934
- Streamline Surgical System$62,850
- Streamline$16,291
- Clearpath$15,591
- Via360$12,124
- OMNI(R) SURGICAL SYSTEM (US)$11,808
- Travoprost Intraocular Implant - iDose$2,700
- SION SURGICAL INSTRUMENT$2,250
- XEN$2,100
- XEN GLAUCOMA TREATMENT SYSTEM$1,587
- iDoseTR$1,301
- iStent Infinite$463
- iStent$431
- iStent Trabecular Micro-Bypass System Model iS3$395
- iStent inject W$388
- IACCESS$260
- DURYSTA$235
- Hydrus$170
- RXSIGHT CONTACT LENS$131
How this compares
$432,059 in reported general payments places this provider in the 95th percentile of 1,405 ophthalmology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 56 | $32,071 |
| RestasisCyclosporine | 20 | $15,671 |
| Alphagan PBrimonidine Tartrate | 30 | $11,037 |
| CombiganBrimonidine Tartrate/Timolol | 28 | $10,869 |
| RocklatanNetarsudil Mesylat/Latanoprost | 13 | $8,498 |
| Prednisolone Acetate | 171 | $7,165 |
| Latanoprost | 616 | $5,876 |
| Brimonidine Tartrate | 78 | $4,372 |
| Timolol Maleate | 157 | $4,339 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 196 | $4,070 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 16 | $2,740 |
| MoxifloxacinMoxifloxacin Hcl | 146 | $2,470 |
| Brinzolamide | 18 | $2,443 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 17 | $2,353 |
| Ketorolac Tromethamine | 80 | $1,518 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Alphagan P, Combigan | $4,730 | $69,648134 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $75 | $8,49813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,405 ophthalmology providers in Florida.
Other ophthalmology in Jacksonville
- Frank BowdenJacksonville$169K
- David KostickJacksonville$108K
- Cathleen McCabeBradenton$2M
- Daniel KiernanSarasota$1.7M
- David EichenbaumSt Petersburg$1.7M
- Mark MilnerPalm Beach Gardens$1.2M
- Neel DesaiLargo$1M
- Jorge FortunPalm Beach Gardens$798K
- Courtney BoveeTampa$796K
- Harold BrooksTallahassee$683K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.